May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Gp100 Peptide Vaccine for Intraocular Melanoma
Author Affiliations & Notes
  • L. Ly
    Leiden Univ Medical Centre, Leiden, The Netherlands
    Ophthalmology,
  • M. Sluijter
    Leiden Univ Medical Centre, Leiden, The Netherlands
    Immunohematology,
  • M. Kouch-el Filali
    Leiden Univ Medical Centre, Leiden, The Netherlands
    Ophthalmology,
  • G. P. M. Luyten
    Leiden Univ Medical Centre, Leiden, The Netherlands
    Ophthalmology,
  • R. Offringa
    Leiden Univ Medical Centre, Leiden, The Netherlands
    Immunohematology,
  • M. J. Jager
    Leiden Univ Medical Centre, Leiden, The Netherlands
    Ophthalmology,
  • M. J. B. van Stipdonk
    Leiden Univ Medical Centre, Leiden, The Netherlands
    Ophthalmology,
  • Footnotes
    Commercial Relationships  L. Ly, None; M. Sluijter, None; M. Kouch-el Filali, None; G.P.M. Luyten, None; R. Offringa, None; M.J. Jager, None; M.J.B. van Stipdonk, None.
  • Footnotes
    Support  NWO Mozaiek
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 4755. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L. Ly, M. Sluijter, M. Kouch-el Filali, G. P. M. Luyten, R. Offringa, M. J. Jager, M. J. B. van Stipdonk; Gp100 Peptide Vaccine for Intraocular Melanoma. Invest. Ophthalmol. Vis. Sci. 2008;49(13):4755. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : Melanoma cells express the protein gp100. The effectiveness of immunotherapy based on gp100 peptide vaccination was tested in a well established intraocular B16F10 eye melanoma model.

Methods: : C57Bl/6 mice were adoptively transferred with T cell receptor-transgenic, human gp100 specific CD8+ T lymphocytes (pmel). Mice received a total of 4 subcutaneous injections with gp100 peptide, starting 2 weeks before tumor inoculation. Immunostimulatory cream containing the TLR-7 ligand Imiquimod (AldaraTM) was applied at the injection site. Some mice were additionally treated with IL-2 i.v. One week after the second vaccination, B16F10 melanoma cells were inoculated in the anterior chamber of the mouse eye. Tumor growth was followed with binocular microscopy and scored semi-quantitatively.

Results: : Tumor growth in the group treated with adoptive transfer of CD8+ cells, gp100 vaccination and Aldara showed a delay in tumor growth. Adding IL-2 intravenously one week before tumor inoculation prevented growth of a B16F10 tumor in the anterior chamber of the eye.

Conclusions: : Immunotherapy consisting of pmel cells, gp100 peptide vaccination and AldaraTM cream delays tumor growth in the eye. Additional treatment with IL-2 induces complete protection against tumor growth of a B16F10 tumor in the anterior chamber of the eye of a C57/Bl6 mouse.

Keywords: oncology • immunomodulation/immunoregulation • tumors 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×